Top Markets
Coin of the day
Cyfuse Biomedical K.K. Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K.

4892
Rank in Stocks #26815
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K.... Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
Share Price
$3.72
Market Cap
$37.53M
Change (1 day)
4.78%
Change (1 year)
-18.34%
Country
JP
Trade Cyfuse Biomedical K.K. (4892)

Category

Operating Margin for Cyfuse Biomedical K.K. (4892)
Operating Margin as of 2026 TTM: 0.00%
According to Cyfuse Biomedical K.K. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Cyfuse Biomedical K.K. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
25.72% -
AU
-149.01% -
US
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.